Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes

Publication date: 23 March 2017
Source:Cell, Volume 169, Issue 1
Author(s): Kfir Sharabi, Hua Lin, Clint D.J. Tavares, John E. Dominy, Joao Paulo Camporez, Rachel J. Perry, Roger Schilling, Amy K. Rines, Jaemin Lee, Marc Hickey, Melissa Bennion, Michelle Palmer, Partha P. Nag, Joshua A. Bittker, José Perez, Mark P. Jedrychowski, Umut Ozcan, Steve P. Gygi, Theodore M. Kamenecka, Gerald I. Shulman, Stuart L. Schreiber, Patrick R. Griffin, Pere Puigserver
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D. Thus, we designed a high-throughput chemical screen platform to quantify PGC-1α acetylation in cells and identified small molecules that increase PGC-1α acetylation, suppress gluconeogenic gene expression, and reduce glucose production in hepatocytes. On the basis of potency and bioavailability, we selected a small molecule, SR-18292, that reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D. These studies have important implications for understanding the regulatory mechanisms of glucose metabolism and treatment of T2D.

Graphical abstract

Teaser

A small molecule targeting gluconeogenesis improves glucose homeostasis in animals with type 2 diabetes, suggesting a new therapeutic approach for this metabolic disease.


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2n19bkc
via IFTTT